AAAAAA

   
Results: 1-10 |
Results: 10
LIMIT OF QUANTIFICATION (FUNCTIONAL SENSITIVITY) OF THE NEW IMX TACROLIMUS-II MICROPARTICLE ENZYME-IMMUNOASSAY
Authors: SCHAMBECK CM BEDEL A KELLER F
Citation: Cm. Schambeck et al., LIMIT OF QUANTIFICATION (FUNCTIONAL SENSITIVITY) OF THE NEW IMX TACROLIMUS-II MICROPARTICLE ENZYME-IMMUNOASSAY, Clinical chemistry, 44(10), 1998, pp. 2217-2217
HYPOTHYROIDISM AND CREATINE-KINASE
Authors: SCHAMBECK CM
Citation: Cm. Schambeck, HYPOTHYROIDISM AND CREATINE-KINASE, Deutsche Medizinische Wochenschrift, 122(21), 1997, pp. 701-701
TRANSIENT ALKALINE HYPERPHOSPHATASEMIA IN AN ADULT - BIOCHEMICAL PECULIARITIES
Authors: SCHAMBECK CM KOPP A MORAMAZA G KELLER F
Citation: Cm. Schambeck et al., TRANSIENT ALKALINE HYPERPHOSPHATASEMIA IN AN ADULT - BIOCHEMICAL PECULIARITIES, European journal of clinical chemistry and clinical biochemistry, 35(6), 1997, pp. 441-444
ENHANCED RISK OF VENOUS THROMBOEMBOLISM IN FACTOR-V-LEIDEN CARRIERS ON ORAL-CONTRACEPTIVE USE - RATIONALE FOR A LIMITED SCREENING FOR THE MUTATION
Authors: SCHAMBECK CM GROSSMANN R HAUBITZ I SCHEUER H SCHMITT R SCHWAB J SCHWENDER S SPENGLER A KELLER F
Citation: Cm. Schambeck et al., ENHANCED RISK OF VENOUS THROMBOEMBOLISM IN FACTOR-V-LEIDEN CARRIERS ON ORAL-CONTRACEPTIVE USE - RATIONALE FOR A LIMITED SCREENING FOR THE MUTATION, Thrombosis and haemostasis, 1997, pp. 1260-1260
SELECTIVE SCREENING FOR THE FACTOR-V-LEIDEN MUTATION - IS IT ADVISABLE PRIOR TO THE PRESCRIPTION OF ORAL-CONTRACEPTIVES
Authors: SCHAMBECK CM SCHWENDER S HAUBITZ I GEISEN UE GROSSMANN RE KELLER F
Citation: Cm. Schambeck et al., SELECTIVE SCREENING FOR THE FACTOR-V-LEIDEN MUTATION - IS IT ADVISABLE PRIOR TO THE PRESCRIPTION OF ORAL-CONTRACEPTIVES, Thrombosis and haemostasis, 78(6), 1997, pp. 1480-1483
CYFRA-21-1 QUANTITY MEASUREMENT IN THE URINE OF PATIENTS WITH CARCINOMA OF THE URINARY-BLADDER AND TRACT
Authors: SCHAMBECK CM STIEBER P SCHMELLER N HOFMANN K PAHL H FATEHMOGHADAM A
Citation: Cm. Schambeck et al., CYFRA-21-1 QUANTITY MEASUREMENT IN THE URINE OF PATIENTS WITH CARCINOMA OF THE URINARY-BLADDER AND TRACT, Anticancer research, 17(4B), 1997, pp. 3063-3065
CHARACTERIZATION OF MYELOMA CELLS BY MEANS OF LABELING INDEX, BONE-MARROW HISTOLOGY, AND SERUM BETA(2)-MICROGLOBULIN
Authors: SCHAMBECK CM BARTL R HOCHTLENVOLLMAR W WICK M LAMERZ R FATEHMOGHADAM A
Citation: Cm. Schambeck et al., CHARACTERIZATION OF MYELOMA CELLS BY MEANS OF LABELING INDEX, BONE-MARROW HISTOLOGY, AND SERUM BETA(2)-MICROGLOBULIN, American journal of clinical pathology, 106(1), 1996, pp. 64-68
EVALUATION OF THE COBAS CORE IMMUNOASSAY FOR MEASURING PROSTATE-SPECIFIC ANTIGEN (PSA) - MULTICENTER STUDY RESULTS
Authors: SCHAMBECK CM
Citation: Cm. Schambeck, EVALUATION OF THE COBAS CORE IMMUNOASSAY FOR MEASURING PROSTATE-SPECIFIC ANTIGEN (PSA) - MULTICENTER STUDY RESULTS, European journal of clinical chemistry and clinical biochemistry, 33(8), 1995, pp. 541-547
METHODOLOGICAL AND CLINICAL COMPARISON OF THE ACS PROSTATE-SPECIFIC ANTIGEN-ASSAY AND THE TANDEM-E PROSTATE-SPECIFIC ANTIGEN-ASSAY IN PROSTATE-CANCER
Authors: SCHAMBECK CM SCHMELLER N STIEBER P JANSEN HM PAHL H SCHNEIDER W FATEHMOGHADAM A
Citation: Cm. Schambeck et al., METHODOLOGICAL AND CLINICAL COMPARISON OF THE ACS PROSTATE-SPECIFIC ANTIGEN-ASSAY AND THE TANDEM-E PROSTATE-SPECIFIC ANTIGEN-ASSAY IN PROSTATE-CANCER, Urology, 46(2), 1995, pp. 195-199
PLASMA-CELL PROLIFERATION IN MONOCLONAL GAMMOPATHIES - MEASUREMENT USING BU-1 ANTIBODY IN FLOW-CYTOMETRY AND MICROSCOPY - COMPARISON WITH SERUM THYMIDINE KINASE
Authors: SCHAMBECK CM WICK M BARTL R LAMERZ R FATEHMOGHADAM A
Citation: Cm. Schambeck et al., PLASMA-CELL PROLIFERATION IN MONOCLONAL GAMMOPATHIES - MEASUREMENT USING BU-1 ANTIBODY IN FLOW-CYTOMETRY AND MICROSCOPY - COMPARISON WITH SERUM THYMIDINE KINASE, Journal of Clinical Pathology, 48(5), 1995, pp. 477-481
Risultati: 1-10 |